Journal of Gastroenterology

, Volume 48, Issue 7, pp 830–838

Comparison of gastrointestinal adverse effects between cyclooxygenase-2 inhibitors and non-selective, non-steroidal anti-inflammatory drugs plus proton pump inhibitors: a systematic review and meta-analysis

  • Saharat Jarupongprapa
  • Prapassorn Ussavasodhi
  • Wanruchada Katchamart
Original Article—Alimentary Tract



There are conflicting and inconsistent data regarding the gastrointestinal (GI) protective effect of cyclooxygenase-2 (COX-2) inhibitors and of non-steroidal anti-inflammatory drugs (NSAIDs) plus proton-pump inhibitors (PPI).


To compare the adverse GI effects between COX-2 inhibitors and NSAIDs plus PPI.


We performed a systematic review of randomized trials comparing GI adverse effects between COX-2 inhibitors and NSAID plus PPI. Trials were identified in MEDLINE, EMBASE, and the Cochrane Library. Primary outcomes were major GI complications including hemorrhage, perforation, and obstruction.


A total of nine trials involving 7,616 participants from 2002 to 2011 were included. All trials were randomized, double blinded, and placebo-controlled with moderate to high quality. COX-2 inhibitors were found to have significantly reduced the risk of major GI events, including perforation, obstruction, and bleeding (relative risk or RR 0.38, 95 % confidence interval or CI 0.25–0.56, p < 0.001); however, the benefit was significant only for patients who were at high risk for NSAID-related GI complications and long-term users. Additionally, the risk of diarrhea (RR 0.56, 95 % CI 0.35–0.9, p 0.02) and withdrawal (RR 0.77, 95 % CI 0.62–0.94, p 0.01) was significantly lower in use of COX-2 inhibitors, while the rate of dyspepsia was higher (RR 1.58, 95 % CI 1.26–1.98, p < 0.001).


COX-2 inhibitors significantly reduced the risk of perforation, obstruction, bleeding, diarrhea, and withdrawal due to GI adverse events, while the risk of dyspepsia was lower with NSAIDs plus PPI.


Cyclooxygenase-2 inhibitors Non-selective Non-steroidal anti-inflammatory drugs Proton-pump inhibitors Gastrointestinal toxicity Meta-analysis 

Supplementary material

535_2012_717_MOESM1_ESM.doc (32 kb)
Supplementary material 1 (DOC 31 kb)


  1. 1.
    Lee M, Feldman M. The aging stomach: implications for NSAID gastropathy. Gut. 1997;41:425–6.PubMedCrossRefGoogle Scholar
  2. 2.
    Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol. 1999;56:18–24.Google Scholar
  3. 3.
    Aalykke C, Lauritsen K. Epidemiology of NSAID-related gastroduodenal mucosal injury. Best Pract Res Clin Gastroenterol. 2001;15:705–22.PubMedCrossRefGoogle Scholar
  4. 4.
    Wolfe M, Lichtenstein D, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med. 1999;40:1888–99.CrossRefGoogle Scholar
  5. 5.
    Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology. 2001;120:594–606.PubMedCrossRefGoogle Scholar
  6. 6.
    Hernandez-Diaz S, Garcia-Rodriguez LA. Epidemiologic assessment of the safety of conventional nonsteroidal anti-inflammatory drugs. Am J Med. 2001;110:20S–7S.PubMedCrossRefGoogle Scholar
  7. 7.
    Scheiman JM, Fendrick AM. Summing the risk of NSAID therapy. Lancet. 2007;369:1580–1.PubMedCrossRefGoogle Scholar
  8. 8.
    Allison MC, Howatson AG, Torrance CJ, Lee FD, Russell RI. Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs. N Engl J Med. 1992;327:749–54.PubMedCrossRefGoogle Scholar
  9. 9.
    Graham DY, Opekun AR, Willingham FF, Qureshi WA. Visible small-intestinal mucosal injury in chronic NSAID users. Clin Gastroenterol Hepatol. 2005;3:55–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Smale S, Tibble J, Sigthorsson G, Bjarnason I. Epidemiology and differential diagnosis of NSAID-induced injury to the mucosa of the small intestine. Best Pract Res Clin Gastroenterol. 2001;15:723–38.PubMedCrossRefGoogle Scholar
  11. 11.
    Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med. 1991;115:787–96.PubMedCrossRefGoogle Scholar
  12. 12.
    Lanas A, Bajador E, Serrano P, et al. Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med. 2000;343:834–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Bjarnason I, Takeuchi K. Intestinal permeability in the pathogenesis of NSAID-induced enteropathy. J Gastroenterol. 2009;44:23–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Chan FKL, Cryer B, Goldstein JL, et al. A novel composite endpoint to evaluate the gastrointestinal (GI) effects of nonsteroidal antiinflammatory drugs through the entire GI tract. J Rheumatol. 2010;37:167–74.PubMedCrossRefGoogle Scholar
  15. 15.
    Graham DY, Chan FKL. NSAIDs, risks, and gastroprotective strategies: current status and future. Gastroenterology. 2008;134:1240–6.PubMedCrossRefGoogle Scholar
  16. 16.
    Lanza FL. A guideline for the treatment and prevention of NSAID-induced ulcers. Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol. 1998;93:2037–46.PubMedCrossRefGoogle Scholar
  17. 17.
    Rostom A, Dube C, Wells G, Tugwell P, Welch V, McGowan J. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev. 2002;4:CD002296.PubMedGoogle Scholar
  18. 18.
    Kamath CC, Kremers HM, Vanness DJ, O’Fallon WM, Cabanela RL, Gabriel SE. The cost-effectiveness of acetaminophen, NSAIDs, and selective COX-2 inhibitors in the treatment of symptomatic knee osteoarthritis. Value Health. 2003;6:144–57.PubMedCrossRefGoogle Scholar
  19. 19.
    Kristiansen IS, Kvien TK. Cost-effectiveness of replacing NSAIDs with coxibs: diclofenac and celecoxib in rheumatoid arthritis. Expert Rev Pharmacoecon Outcomes Res. 2002;2:229–41.PubMedCrossRefGoogle Scholar
  20. 20.
    Latimer N, Lord J, Grant RL, et al. Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis. BMJ. 2009;339:b2538.PubMedCrossRefGoogle Scholar
  21. 21.
    Schnitzer TJ, Burmester GR, Mysler E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet. 2004;364:665–74.PubMedCrossRefGoogle Scholar
  22. 22.
    You JHS, Lee KKC, Chan TYK, Lau WH, Chan FKL. Arthritis treatment in Hong Kong—cost analysis of celecoxib versus conventional NSAIDS, with or without gastroprotective agents. Aliment Pharmacol Ther. 2002;16:2089–96.PubMedCrossRefGoogle Scholar
  23. 23.
    Hiraishi H, Yamagata M, Yoneda M, Shimada T. Guideline for prophylaxis and treatment of NSAID-associated gastric ulcerations. Nihon Rinsho. 2007;65:1812–7.PubMedGoogle Scholar
  24. 24.
    Lanza FL, Chan FKL, Quigley EMM. Practice Parameters Committee of the American College of G. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009;104:728–38.PubMedCrossRefGoogle Scholar
  25. 25.
    Rostom AM, Hun tR, for the Canadian Association of Gastroenterology Consensus Group. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks. Aliment Pharmacol Ther. 2009;29:481–96.PubMedCrossRefGoogle Scholar
  26. 26.
    Chan FKL, Hung LCT, Suen BY, et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med. 2002;347:2104–10.PubMedCrossRefGoogle Scholar
  27. 27.
    Lai K-C, Chu K-M, Hui W-M, et al. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Am J Med. 2005;118:1271–878.PubMedCrossRefGoogle Scholar
  28. 28.
    Ray WA, Chung CP, Stein CM, et al. Risk of peptic ulcer hospitalizations in users of NSAIDs with gastroprotective cotherapy versus coxibs. Gastroenterology. 2007;133:790–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Goldstein J, Cryer B, Amer F, Hunt B. Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial. Clin Gastroenterol Hepatol. 2007;5:1167–74.PubMedCrossRefGoogle Scholar
  30. 30.
    Goldstein JL, Eisen GM, Lewis B, Gralnek IM, Zlotnick S, Fort JG. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol. 2005;3:133–41.PubMedCrossRefGoogle Scholar
  31. 31.
    Wang X, Tian HJ, Yang HK, Wanyan P, Peng YJ. Meta-analysis: cyclooxygenase-2 inhibitors are no better than nonselective nonsteroidal anti-inflammatory drugs with proton pump inhibitors in regard to gastrointestinal adverse events in osteoarthritis and rheumatoid arthritis. Eur J Gastroenterol Hepatol. 2011;23:876–80.PubMedCrossRefGoogle Scholar
  32. 32.
    Assessing risk of bias in included studies, chap. 8. In: Higgins JP, Altman DG, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 500. The Cochrane Collaboration and John Wiley & Sons Ltd; 2008.Google Scholar
  33. 33.
    Chan F, Hung L, Suen B, et al. Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial. Gastroenterology. 2004;127:1038–43.PubMedCrossRefGoogle Scholar
  34. 34.
    Goldstein JL, Eisen GM, Lewis B, et al. Small bowel mucosal injury is reduced in healthy subjects treated with celecoxib compared with ibuprofen plus omeprazole, as assessed by video capsule endoscopy. Aliment Pharmacol Ther. 2007;25:1211–22.PubMedCrossRefGoogle Scholar
  35. 35.
    Chan FKL, Lanas A, Scheiman J, Berger MF, Nguyen H, Goldstein JL. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet. 2010;376:173–9.PubMedCrossRefGoogle Scholar
  36. 36.
    Hawkey CJ, Ell C, Simon B, et al. Less small-bowel injury with lumiracoxib compared with naproxen plus omeprazole. Clin Gastroenterol Hepatol. 2008;6:536–44.PubMedCrossRefGoogle Scholar
  37. 37.
    Cryer BL, Sostek MB, Fort JG, Svensson O, Hwang C, Hochberg MC. A fixed-dose combination of naproxen and esomeprazole magnesium has comparable upper gastrointestinal tolerability to celecoxib in patients with osteoarthritis of the knee: results from two randomized, parallel-group, placebo-controlled trials. Ann Med. 2011;43:594–605.PubMedCrossRefGoogle Scholar
  38. 38.
    Lanas A, Panes J, Pique JM. Clinical implications of COX-1 and/or COX-2 inhibition for the distal gastrointestinal tract. Curr Pharm Des. 2003;9:2253–66.PubMedCrossRefGoogle Scholar
  39. 39.
    FDA Drug Safety Communication. Clostridium difficile-associated diarrhea can be associated with stomach acid drugs known as proton pump inhibitors (PPIs). 2012.

Copyright information

© Springer Japan 2012

Authors and Affiliations

  • Saharat Jarupongprapa
    • 1
  • Prapassorn Ussavasodhi
    • 2
  • Wanruchada Katchamart
    • 2
  1. 1.Department of MedicineNakornprathom HospitalNakornprathomThailand
  2. 2.Division of Rheumatology, Department of Medicine Siriraj HospitalMahidol UniversityBangkokThailand

Personalised recommendations